Physician profile
Timothy Eng
NPI 1730685231
$5,230.30
in general payments reported to CMS, 2019-2025
23 companies · $1,617 in 2025
The $1,617 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.68 · 2022: $867 · 2023: $710 · 2024: $2,018 · 2025: $1,617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,345.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $897.38 | 2022-2025 | Arexvy, Trelegy Ellipta |
| Gilead Sciences, INC. | $596.01 | 2022-2025 | Vemlidy |
| Abbvie INC. | $485.92 | 2024-2025 | |
| Madrigal Pharmaceuticals | $407.11 | 2025 | Rezdiffra |
| Otsuka America Pharmaceutical, INC. | $342.97 | 2022-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $295.84 | 2024-2025 | Voquezna |
| Angiodynamics, INC. | $260.48 | 2024 | Angiodynamics, Nanoknife |
| Amgen INC. | $257.93 | 2023-2025 | Evenity, Prolia, Prolia |
| Medtronic, INC. | $200.14 | 2022 | |
| Ibsa Pharma INC. | $199.16 | 2022-2024 | Licart, Tirosint, Tirosint |
| Exact Sciences Corporation | $194.90 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $151.68 | 2024-2025 | Airsupra |
| Sirtex Medical INC | $134.49 | 2023 | Sir-Spheres Microspheres |
| Globus Medical, INC. | $133.67 | 2024 | Rise-L . Rise-L A/L |
| Axsome Therapeutics, INC. | $125.00 | 2025 | Auvelity |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $125.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2024 | |
| Agios Pharmaceuticals, INC. | $124.97 | 2025 | Pyrukynd |
| Novo Nordisk INC | $49.89 | 2023 | Rybelsus, Ozempic |
| Vbi Vaccine (Delaware) INC. | $33.95 | 2022 | |
| Merck Sharp & Dohme LLC | $32.58 | 2021-2022 | |
| Pfizer INC. | $32.13 | 2024-2025 | |
| Viiv Healthcare Company | $24.10 | 2025 | Apretude |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Eng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.